Novartis (NVS) stock
NVS · Novartis AG · NYSE
- Market cap
- $287.13B
- Shares out
- 1.91B
What is the latest news on NVS stock?
NVS fell 0.50% to $150.47 on Nov 20, 2026. No NVS story in the last two days; the most recent is below.
6-K - NOVARTIS AG (0001114448) (Filer)
All NVS newsWhen does Novartis report earnings?
The latest Novartis earnings release came out on Dec 2, 2024: PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program. Before that, Novartis reported on Mar 8, 2022.
NVS earnings historyWho owns the most NVS stock?
Fisher Asset Management, LLC was the largest reported holder of NVS at the end of Q2 2026, with 15,523,378 shares worth $2.4 billion. Next came Morgan Stanley ($1.4 billion) and Dimensional Fund Advisors LP ($1.3 billion). In all, 1,618 institutions reported $21.3 billion of NVS in their 13F filings.
All NVS fund holdersFinancial highlights
Full financials- Revenue, FY2025
- $54.53B
- Revenue growth
- +8.4%
- Net income, FY2025
- $13.98B
- Net margin
- 25.6%
- Free cash flow, FY2025
- $17.60B
- Cash
- $11.44B
For fiscal 2025 (ended Dec 31, 2025), from SEC filings. Not investment advice.
Latest news
25 items- SECSEC Form 6-K filed by Novartis AG6-K - NOVARTIS AG (0001114448) (Filer)
- SECSEC Form 6-K filed by Novartis AG6-K - NOVARTIS AG (0001114448) (Filer)
- SECSEC Form FWP filed by Novartis AGFWP - NOVARTIS AG (0001114448) (Subject)
- FDAFDA Approval for LAMPRENE issued to NOVARTISSubmission status for NOVARTIS's drug LAMPRENE (SUPPL-15) with active ingredient CLOFAZIMINE has changed to 'Approval' on 11/03/2026. Application Category: NDA, Application Number: 019500, Application Classification: Labeling
- ANALYSTNovartis AG downgraded by Deutsche BankDeutsche Bank downgraded Novartis AG from Hold to Sell
- SECSEC Form 6-K filed by Novartis AG6-K - NOVARTIS AG (0001114448) (Filer)
- PRBig Pharma Setbacks Create a New Wave of Rebound PlaysDENVER, Sept. 10, 2026 (GLOBE NEWSWIRE) -- The biotech tape delivered a brutal reminder of one of the sector’s oldest rules: even a fundamentally strong company can get caught in the crossfire when a major drugmaker suffers a pipeline setback. Yesterday, a setback at Novartis (NYSE:NVS) sent ripples across the biotech space, pressuring companies whose own clinical and corporate announcements remained decidedly positive. The resulting selloff highlighted just how quickly investors can shift from company-specific fundamentals to broader sector risk. For smaller biotech names, that indiscriminate pressure can be painful, but it can also create potentially compelling rebound setups when posit
- ANALYSTNovartis AG upgraded by HSBC SecuritiesHSBC Securities upgraded Novartis AG from Reduce to Hold
- PRHistoric First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics MarketAUSTIN, Texas, Sept. 10, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Today's multiple sclerosis treatments can slow down disease progression, but none of them halt it outright, and none give back the function patients have already lost. Close to a million people in the United States, and nearly 2.9 million worldwide, live with that reality, watching a condition that steadily chips away at mobility, eyesight and basic physical control. That gap in treatment options just picked up a serious new contender. Quantum BioPharma Ltd. (NASDAQ:QNTM) (profile) has received U.S. Food and Drug Administration ("FDA") clearance to launch a phase 2 trial of Lucid-MS, a patented, first-in-class
- ANALYSTRBC Capital Mkts initiated coverage on Novartis AGRBC Capital Mkts initiated coverage of Novartis AG with a rating of Sector Perform
- ANALYSTNovartis AG downgraded by Deutsche BankDeutsche Bank downgraded Novartis AG from Buy to Hold
- SECSEC Form 6-K filed by Novartis AG6-K - NOVARTIS AG (0001114448) (Filer)
- SECSEC Form 6-K filed by Novartis AG6-K - NOVARTIS AG (0001114448) (Filer)
- SECSEC Form 6-K filed by Novartis AG6-K - NOVARTIS AG (0001114448) (Filer)
- SECSEC Form 6-K filed by Novartis AG6-K - NOVARTIS AG (0001114448) (Filer)
- PRThe Quest to Repair What Multiple Sclerosis Takes AwayAUSTIN, Texas, June 24, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Multiple sclerosis ("MS") gradually strips people of command over their own bodies, advancing steadily with no available cure. More than 2.9 million people across the globe are currently living with the disease. But even with generations of scientific study and research, every approved treatment still falls short of one essential objective: bringing the disease to a complete stop. Existing therapies can slow its advance, but none can halt it outright. That shortfall translates into a future of mounting disability for millions of MS sufferers. Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (profile) is determin
- SECSEC Form 6-K filed by Novartis AG6-K - NOVARTIS AG (0001114448) (Filer)
- SECSEC Form 6-K filed by Novartis AG6-K - NOVARTIS AG (0001114448) (Filer)
- SECSEC Form 6-K filed by Novartis AG6-K - NOVARTIS AG (0001114448) (Filer)
- ANALYSTNovartis AG upgraded by Argus with a new price targetArgus upgraded Novartis AG from Hold to Buy and set a new price target of $180.00
- PRNovartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategyAdds Avidity's differentiated muscle-directed Antibody Oligonucleotide Conjugates (AOC) platform and three late-stage programs to industry-leading neuromuscular pipelinePotentially unlocks multi-billion-dollar opportunities with planned product launches before 2030Strengthens late-stage pipeline to further support 2025-2030 net sales CAGR of 5-6% cc and mid to long term growth outlook Basel, February 27, 2026 -- Novartis AG (NYSE:NVS) today announced that it has successfully completed its acquisition of Avidity Biosciences, Inc. ("Avidity"). With the completion of the acquisition, Avidity is now an indirect, wholly owned subsidiary of Novartis. "Avidity's breakthrough science combined with
- SECSEC Form S-8 filed by Novartis AGS-8 - NOVARTIS AG (0001114448) (Filer)
- SECSEC Form 6-K filed by Novartis AG6-K - NOVARTIS AG (0001114448) (Filer)
- SECSEC Form 6-K filed by Novartis AG6-K - NOVARTIS AG (0001114448) (Filer)
- SECSEC Form IRANNOTICE filed by Novartis AGIRANNOTICE - NOVARTIS AG (0001114448) (Filer)
NVS rankings
- SEC Filings7(50%)
- Analyst4(29%)
- Other2(14%)
- Offering1(7%)
Our reporting on NVS
- Pfizer's $1.5B revenue guide raise is 2.1x its Q3 beat, but the $0.10 EPS raise trails the $0.14 beat as revenue slips 0.4%Analysis · Nov 3, 2026 · 6 min read

- Deutsche Bank Cuts Novartis to Sell With a CHF 115 Target as a $2.2 Billion Pipeline Charge Overshadows a Q3 BeatAnalysis · Oct 31, 2026 · 6 min read

- Oppenheimer upgrades Incyte to Outperform at $144 as Jakafi supplies only 21% of Q3 sales growth and price drag hits $67.4 millionAnalysis · Oct 30, 2026 · 7 min read

- Tech falls 4.90% as Intel's 28.58% drop drags the Nasdaq 100 down 3.48%, while equal weight loses only 0.78% and INO jumps after hoursPost-close recap · Oct 30, 2026 · 7 min read

Novartis AG (NVS) is a Biotechnology: Pharmaceutical Preparations company listed on NYSE. In the last 30 days Quantisnow tracked 6 wire items for NVS, including 4 SEC filings, 1 analyst rating and 1 press release or news item. The most recent was published Nov 19, 2026.
NVS FAQ
9 questionsWhat does Novartis AG do?
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic...What is NVS revenue?
Novartis AG (NVS) reported $54.53B of revenue for fiscal 2025 (ended Dec 31, 2025). That is up 8.4% from the year before.Is NVS profitable?
Yes. Novartis AG earned $13.98B in net income for fiscal 2025 (ended Dec 31, 2025), a net margin of 25.6%.How much cash and debt does NVS have?
Novartis AG reported $11.44B in cash and cash equivalents and $28.73B of debt on its most recent balance sheet in SEC filings.Where does NVS stock trade?
Novartis AG (NVS) is listed on NYSE.What sector and industry is NVS in?
Novartis AG operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about NVS?
Across the last 8 analyst actions on Novartis AG, there were 4 upgrades and 2 downgrades. The most recent action was from Deutsche Bank: Sell on 2026-10-30. Recent price targets cluster around $180.00.What companies are similar to NVS?
Notable peers in the same industry include JNJ (Johnson & Johnson), MRK (Merck & Company Inc.), SNY (Sanofi), PFE (Pfizer Inc.), AZN (AstraZeneca PLC). Compare NVS side-by-side with any of them on Quantisnow.How can I track NVS on Quantisnow?
Quantisnow aggregates Novartis AG's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NVS to receive live email and push alerts on every new disclosure.
Is something on this page wrong, or out of date? Request a change